GlassScriptPhysician profile
Amy D Smith
NPI 1841060852
$3,085.09
in general payments reported to CMS, 2019-2025
35 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 90% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $121 · 2024: $1,759 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,801 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,801.11 |
| Education | $283.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $484.38 | 2024 | Myrisk |
| Janssen Biotech, INC. | $339.58 | 2024-2025 | Tecvayli, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $325.49 | 2024-2025 | Calquence, Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $233.82 | 2023-2025 | |
| Seagen INC. | $184.98 | 2025 | |
| Merck Sharp & Dohme LLC | $178.82 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Glaxosmithkline, LLC. | $143.71 | 2024 | Ojjaara |
| Amgen INC. | $137.69 | 2024 | Lumakras, Prolia, Evenity |
| Astellas Pharma US INC | $133.97 | 2024 | Padcev |
| Pfizer INC. | $124.65 | 2025 | |
| Sumitomo Pharma America, INC. | $94.52 | 2024-2025 | Orgovyx |
| Siemens Medical Solutions USA, INC. | $53.11 | 2023-2025 | Truebeam, Biograph Vision 600 (8 Ring/64 Ct) |
| Pharmaessentia USA Corporation | $51.63 | 2024-2025 | Besremi |
| Incyte Corporation | $49.80 | 2024-2025 | Monjuvi, Zynyz, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $49.40 | 2024 | Opdualag, Opdivo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $49.39 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.46 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $39.97 | 2025 | Monoferric |
| Stemline Therapeutics INC. | $32.24 | 2023-2025 | Orserdu |
| Novocure INC. | $31.32 | 2025 | Optune Lua (Novottf-200t) |
| Lilly USA, LLC | $26.54 | 2025 | Jaypirca, Verzenio |
| Ferring Pharmaceuticals INC. | $25.15 | 2025 | Adstiladrin |
| Abbvie INC. | $24.81 | 2025 | |
| Progenics Pharmaceuticals, INC. | $24.55 | 2024 | |
| Sobi, INC | $24.20 | 2024 | |
| Jazz Pharmaceuticals INC. | $20.07 | 2025 | |
| Genentech USA, INC. | $19.13 | 2025 | Phesgo |
| Coherus Oncology, INC. | $18.44 | 2024 | |
| Genmab U.S., INC. | $18.13 | 2025 | Tivdak |
| Daiichi Sankyo INC. | $16.86 | 2024 | Enhertu |
| Immunocore Limited | $16.56 | 2024 | Kimmtrak |
| Regeneron Healthcare Solutions, INC. | $16.51 | 2025 | Libtayo |
| Taiho Oncology, INC. | $16.40 | 2025 | |
| Alnylam Pharmaceuticals INC. | $15.53 | 2025 | Givlaari |
| Morphosys, US INC. | $15.28 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.